Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding.

International Journal of Molecular Sciences
Christophe DesterkeAli G Turhan

Abstract

Chronic myeloid leukemia (CML) is characterized by an inherent genetic instability, which contributes to the progression of the disease towards an accelerated phase (AP) and blast crisis (BC). Several cytogenetic and genomic alterations have been reported in the progression towards BC, but the precise molecular mechanisms of this event are undetermined. Transcription Factor 7 like 2 (TFC7L2) is a member of the TCF family of proteins that are known to activate WNT target genes such as Cyclin D1. TCF7L2 has been shown to be overexpressed in acute myeloid leukemia (AML) and represents a druggable target. We report here that TCF7L2 transcription factor expression was found to be correlated to blast cell numbers during the progression of the disease. In these cells, TCF7L2 CHIP-sequencing highlighted distal cis active enhancer, such as elements in SMAD3, ATF5, and PRMT1 genomic regions and a proximal active transcriptional program of 144 genes. The analysis of CHIP-sequencing of MYC revealed a significant overlapping of TCF7L2 epigenetic program with MYC. The β-catenin activator lithium chloride and the MYC-MAX dimerization inhibitor 10058-F4 significantly modified the expression of three epigenetic targets in the BC cell line K562....Continue Reading

References

Sep 18, 1992·Cell·C L SawyersO N Witte
Oct 13, 2001·Genome Biology·P Pavlidis, W S Noble
Dec 3, 2005·Genes & Development·Joan MassaguéDavid Wotton
Feb 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jerald P RadichPeter S Linsley
May 23, 2006·Biochemical and Biophysical Research Communications·Kenji FurunoKen Yamamoto
Oct 13, 2006·Journal of Molecular Endocrinology·Liran ZhouZhengxin Wang
Feb 27, 2007·Trends in Cell Biology·Peter Gallant
Jan 25, 2008·The Journal of Biological Chemistry·Zhengyu Liu, Joel F Habener
Feb 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Su-Jiang ZhangSai-Juan Chen
Feb 13, 2008·Molecular and Cellular Biology·Pantelis HatzisHendrik G Stunnenberg
Aug 30, 2008·Nature·Franz-Josef MüllerJeanne F Loring
Sep 2, 2008·Cancer Research·Otmar HuberJean Rosenbaum
May 4, 2010·Nature Biotechnology·Cory Y McLeanGill Bejerano
Jan 12, 2011·Nature Biotechnology·James T RobinsonJill P Mesirov
Jan 11, 2012·Nature Structural & Molecular Biology·Valentina MiglioriErnesto Guccione
May 5, 2012·Nucleus·Salvatore Spicuglia, Laurent Vanhille
Oct 17, 2012·Proceedings of the National Academy of Sciences of the United States of America·Stephen AntonysamySpencer Emtage
Nov 23, 2013·Nature Protocols·Su WangX Shirley Liu
May 7, 2014·Nucleic Acids Research·Fidel RamírezThomas Manke
Mar 27, 2016·Experimental Hematology·Frank J T StaalHarald Mikkers
Jun 10, 2016·Nature·Sheela A AbrahamTessa L Holyoake
Aug 30, 2016·Cancers·Frank J T StaalKarin Pike-Overzet
Sep 20, 2016·The Journal of Clinical Investigation·Yanli JinJingxuan Pan
Oct 6, 2017·The EMBO Journal·Teerapong SiriboonpiputtanaChi Wai Eric So

❮ Previous
Next ❯

Datasets Mentioned

BETA
GPL2029

Methods Mentioned

BETA
CHIP-seq
acetylation
FCS
PCR

Software Mentioned

Factominer
OmicCircos
PLURINET
Multiexperiment viewer Mev
made4
Integrative Genomics Viewer
deeptools
CML
Cistrome Galaxy
R

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.